X hits on this document

713 views

0 shares

0 downloads

0 comments

8 / 170

TABLE OF CONTENTS April 1, 2009

Call to Order and Introductions Kenneth Burman, MD Committee Chairman Endocrinologic and Metabolic Drugs Advisory Committee (EMAC)

Conflict of Interest Statement Paul Tran, R.Ph. Designated Federal Official EMDAC

Introduction and Background Hylton Joffe, M.D., M.M.Sc. Diabetes Clinical Team Leader Centre for Drug Evaluation and Research (CDER) Division of Metabolism and Endocrinology Products (DMEP)

Sponsor Presentation Bristol-Myers Squibb

Introduction Joseph Lamendola, Ph.D. Global Regulatory Sciences Bristol-Myers Squibb

Overview of Development Program Robert Wolf, M.D., F.A.C.C. Vice President Bristol-Myers Squibb

Clinical Efficacy and Clinical Safety Roland Chen, M.D. Group Director Cardiovascular/Metabolics Bristol-Myers Squibb

Scribes, LLC Toll Free 1-800-675-8846 www.scribesllc.com

Page

9

11

14

28

30

33

7

Document info
Document views713
Page views713
Page last viewedTue Jan 24 09:49:10 UTC 2017
Pages170
Paragraphs7975
Words54271

Comments